Polymorphisms in the promoter region of the CRBN gene as a predictive factor for the first-line CTD therapy in multiple myeloma patients

Oncotarget
Aneta Szudy-SzczyrekMarek Hus

Abstract

Cereblon is a primary molecular target for immunomodulatory drugs. The aim of this study was to evaluate the influence of selected clinical and molecular factors including single nucleotide polymorphisms (SNPs) in CRBN gene on the efficacy of first line CTD (cyclophosphamide, thalidomide, dexamethasone) chemotherapy in patients with multiple myeloma. Study group consisted of 68 patients. Analysis of CRBN gene SNPs (rs6768972, rs1672753) was performed using Real-Time PCR genotyping technique. Median progression free survival (PFS) was 15 months and overall survival (OS) 79 months. Factors associated with significantly shorter OS included ISS 3, kidney disease, weight loss, anemia, thrombocytopenia, hypoalbuminemia, elevated β2-microglobuline and CRP. The presence of t(4;14) was associated with significantly shorter PFS and OS. Both examined SNPs proved to be statistically significant, independent predictive factors of efficacy of the CTD chemotherapy. The presence of AA genotype (rs6768972) correlated with longer median PFS (18 vs 9 months; HR=0.49,95% CI: 0.26-0.91, p=0.0062). Conversely, in the carriers of CC genotype (rs1672753) significantly shorter median PFS was observed (4 vs 16 months; HR=3.93, 95% CI: 0.26-59.64, p=0.03...Continue Reading

References

Nov 24, 1999·The New England Journal of Medicine·S SinghalB Barlogie
Apr 6, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Philip R GreippJan Westin
May 14, 2005·Critical Reviews in Oncology/hematology·Jacques RobertJacques Bonnet
Jul 20, 2006·Current Cancer Drug Targets·Daniel M-Y SzeDouglas Joshua
Feb 28, 2007·Leukemia & Lymphoma·V Eleutherakis-PapaiakovouUNKNOWN Greek Myeloma Study Group
May 16, 2008·International Journal of Laboratory Hematology·S-I FuchidaM Taniwaki
Sep 20, 2008·Clinical Chemistry·Michael J Duffy, John Crown
Jul 30, 2009·Blood·Jean-Luc HarousseauHerve Avet-Loiseau
Nov 7, 2009·Platelets·Zübeyde Nur OzkurtRauf Haznedar
Jan 6, 2011·Cellular and Molecular Life Sciences : CMLS·Takumi ItoHiroshi Handa
Jun 18, 2011·Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology·Kevin D BoydGareth J Morgan
Sep 21, 2013·The Oncologist·Tracey S BeasonKenneth R Carson
Oct 17, 2013·Leukemia Research·Steven R SchusterA Keith Stewart
Jul 2, 2014·European Journal of Haematology·Hirono IriuchishimaYoshihisa Nojima
Oct 18, 2014·Advances in Medical Sciences·Joanna KamińskaHalina Kemona
Nov 13, 2014·Cellular and Molecular Life Sciences : CMLS·Florian T UngerKerstin A David
Jan 9, 2016·CA: a Cancer Journal for Clinicians·Rebecca L SiegelAhmedin Jemal
Jan 14, 2017·Archivum Immunologiae Et Therapiae Experimentalis·Aleksandra ButrymKatarzyna Bogunia-Kubik

❮ Previous
Next ❯

Methods Mentioned

BETA
ISS
PCR
genotyping

Software Mentioned

MedCalc
Statistica

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.